Which companies are Shanghai Serum Bio-Technology's closest peers?

The cockpit's peer set: Neurogene (NGNE), DiaMedica Therapeutics (DMAC), Berry Genomics (000710.SZ), Qurient (115180.KS), Crescent Biopharma (CBIO), HanchorBio (7827.TW), Beijing Scitop Bio-Tech (300858.SZ), Liaoning Dingjide Petrochemical (603255.SS).

Is Shanghai Serum Bio-Technology expensive compared with its peers?

On ev / sales it trades at 13.7× against a peer median of 6.5×, 6th most expensive of 16 in its peer set.

How has Shanghai Serum Bio-Technology stock performed?

Over six months to 6 Nov 2026 the shares returned -11.3% against -14.2% for the median peer; over one year +36.1%.

← CockpitCompetitor Analysis › 688163.SS Shanghai Serum Bio-Technology Co., Ltd. Class AOpen in the cockpit ↗

Shanghai Serum Bio-Technology Co., Ltd. Class A688163.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology

Momentum leader 80

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$507M

US dollars, full cap

Free float

100%

of shares outstanding

$/day

$5.21M

20-day average traded

Fwd P/E

n/m

no positive forecast

ROIC−WACC

+2.9 pp

WACC 9.1%

Hurdle

n/a

no reverse DCF

Close · CNYCN¥31.22

1D-0.5%

1W+2.7%

1M-11.6%

3M+13.7%

6M-11.3%

YTD+43.4%

1Y+36.1%

ATR %7.5%

52w lowhigh41.0% off high

What Shanghai Serum Bio-Technology does

Employees: 330

Shanghai Serum Bio-Technology at a glance

Size Shanghai Serum Bio-Technology (688163.SS) is a China Health Care company (Biotechnology) with a market value of $507M, the 3829th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥31.22 on 6 Nov 2026.

Performance Over six months the shares fell 11.3%, against -14.2% for the median peer and -16.4% for the China market (cap-weighted) — 9th highest of 20 in its peer set.

Growth Revenue fell 1.4% over the last twelve months (peer median -3.5%); the operating margin is 26.0% (peer median -10.8%).

Valuation It trades at 13.7× enterprise value to sales against a peer median of 6.5× (6th most expensive of 16).

Capital Return on invested capital runs 2.9 points above its cost of capital (9.1% WACC).

Relative performance

Six months, rebased to 100: Shanghai Serum Bio-Technology against the median of its 20 peers (local-currency closes).

Shanghai Serum Bio-Technology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	CN¥194M	CN¥195M	CN¥194M	CN¥189M	CN¥174M
Revenue growth	—	+1%	+3%	+9%	—
Gross profit	CN¥162M	CN¥144M	CN¥144M	CN¥138M	CN¥141M
EBITDA	n/a	CN¥71.5M	CN¥66.6M	CN¥50.4M	CN¥66.0M
Net income	CN¥50.6M	CN¥51.8M	CN¥44.3M	CN¥38.8M	CN¥64.2M
Free cash flow	-CN¥17.8M	CN¥11.3M	CN¥7.86M	CN¥21.9M	CN¥57.3M
Capital expenditure	CN¥90.1M	CN¥59.6M	CN¥59.4M	CN¥28.7M	CN¥26.5M
Total debt	CN¥4.59M	CN¥5.10M	CN¥4.30M	CN¥13.0M	CN¥13.7M

Quarterly statements and history in the cockpit →

Shanghai Serum Bio-Technology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Shanghai Serum Bio-Technology is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shanghai Serum Bio-Technology is the large dot.

Shanghai Serum Bio-Technology competitors and peer comparison

How Shanghai Serum Bio-Technology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shanghai Serum Bio-Technology against its 20 peers (data as of 6 Nov 2026)
Measure	688163.SS	Peer median	Rank in peer set
1-month return	-11.6%	-12.4%	9th highest of 21
6-month return	-11.3%	-14.2%	9th highest of 20
Distance from 52-week high	-41.0%	-42.2%	10th highest of 21
Revenue growth (TTM)	-1.4%	-3.5%	7th highest of 15
Operating margin	26.0%	-10.8%	2nd highest of 16
EV / Sales	13.7×	6.5×	6th most expensive of 16
ROIC minus cost of capital	+2.9 pp	-11.3 pp	highest of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g	Delivered g
Shanghai Serum Bio-Technology 688163.SS	China	$507M	-11%	-1%	26%	13.7×	n/a	n/a
Neurogene NGNE	United States	$506M	-18%	-100%	n/a	n/a	n/a	n/a
DiaMedica Therapeutics DMAC	United States	$505M	+48%	n/a	n/a	n/a	n/a	n/a
Berry Genomics 000710.SZ	China	$504M	-5%	-2%	-24%	3.8×	n/a	n/a
Qurient 115180.KS	South Korea	$503M	-59%	-20%	-517%	98.9×	n/a	n/a
Crescent Biopharma CBIO	United States	$503M	-28%	n/a	-1,418%	28.3×	n/a	n/a
HanchorBio 7827.TW	Taiwan	$511M	n/a	n/a	-225%	48.0×	n/a	n/a
Beijing Scitop Bio-Tech 300858.SZ	China	$526M	-25%	+4%	8%	8.0×	n/a	n/a
Liaoning Dingjide Petrochemical 603255.SS	China	$530M	-15%	+70%	5%	5.4×	n/a	n/a
Hvsen Biotechnology 300871.SZ	China	$531M	-33%	+2%	17%	2.2×	n/a	n/a
Scinopharm Taiwan 1789.TW	Taiwan	$482M	-1%	-5%	-4%	5.2×	15.2%	+0.5%
Valneva VLA.PA	France	$534M	-2%	-27%	-87%	4.0×	n/a	n/a
CHO Pharma 6586.TWO	Taiwan	$480M	+57%	-47%	-17,694%	8,168.1×	n/a	n/a
Monopar Therapeutics MNPR	United States	$479M	+12%	n/a	n/a	n/a	n/a	n/a
Sinotherapeutics 688247.SS	China	$537M	-14%	-17%	0%	7.0×	31.6%	+7.0%
Hanx Biopharmaceuticals (Wuhan) 3378.HK	Hong Kong	$469M	-13%	n/a	n/a	n/a	n/a	n/a
Shanghai ZJ Bio-Tech 688317.SS	China	$468M	-16%	-18%	-75%	5.2×	6.0%	-62.3%
Jacobio Pharmaceuticals 1167.HK	Hong Kong	$468M	-27%	+286%	68%	2.5×	-14.9%	-36.1%
Medigen Vaccine Biologics 6547.TWO	Taiwan	$467M	-5%	+44%	10%	18.0×	n/a	n/a
Eupraxia Pharmaceuticals EPRX.TO	Canada	$466M	-5%	n/a	n/a	n/a	n/a	n/a
Beijing Bohui Innovation Biotechnology 300318.SZ	China	$553M	-19%	+6%	-11%	6.5×	n/a	n/a

Questions

Which companies are Shanghai Serum Bio-Technology's closest peers?: The cockpit's peer set: Neurogene (NGNE), DiaMedica Therapeutics (DMAC), Berry Genomics (000710.SZ), Qurient (115180.KS), Crescent Biopharma (CBIO), HanchorBio (7827.TW), Beijing Scitop Bio-Tech (300858.SZ), Liaoning Dingjide Petrochemical (603255.SS).
Is Shanghai Serum Bio-Technology expensive compared with its peers?: On ev / sales it trades at 13.7× against a peer median of 6.5×, 6th most expensive of 16 in its peer set.
How has Shanghai Serum Bio-Technology stock performed?: Over six months to 6 Nov 2026 the shares returned -11.3% against -14.2% for the median peer; over one year +36.1%.